Compare Incyte Corporation (INCY) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs MasterCard Inc — how do they compare? Incyte Corporation trades at $120.65 (market cap $24.54B), while MasterCard Inc trades at $556.98 (market cap $491.83B). The key difference: MasterCard Inc is far larger — about 20× Incyte Corporation's market cap, and MasterCard Inc pays a 0.62% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MA | |
|---|---|---|
Market Cap | $24.54B | $491.83B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $598.96 |
52-Week Low | $81.61 | $471.55 |
Enterprise Value | $20.04B | $504.86B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Mastercard (MA) trades at $563.17, showing stability with a slight 0.04% daily gain. The stock exhibits strong fundamentals, with Q2 2026 EPS beating expectations at $5.04 versus $4.77, and maintains robust profitability with a 46.34% net income margin. Technical indicators signal a bullish trend, supported by moving averages, while analyst consensus is overwhelmingly positive with a $660.85 price target. Recent news highlights institutional acquisitions and strategic initiatives in AI and digital inclusion.
Outlook remains favorable driven by consistent earnings beats and revenue growth, though risks include competitive pressures from emerging payment technologies like stablecoins and high valuation multiples. The stock presents a growth opportunity with solid institutional backing, but investors should monitor execution on innovation and macroeconomic factors affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
